Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AUTO3 CAR T cells targeting CD19 and CD22 reported effective in r/r DLBCL

Publish date:: July 9, 2020

Key clinical point: AUTO3 at > 50 x 10⁶ CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade.

Major finding: Among 11 patients treated at dose > 50 x 10⁶ cells, the ORR and CRR were 64% and 55%, respectively.

Study details: A total of 19 DLBCL patients were treated with AUTO3; 18 of whom were evaluable for efficacy.

Disclosures: The abstract did not provide conflict information.

Citation:

Osborne W et al. European Hematology Association virtual annual meeting. 2020; Abstract S240.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,

All Specialties